ArticleMolecular therapy. Nucleic acids2014
Self-replicating Replicon-RNA Delivery to Dendritic Cells by Chitosan-nanoparticles for Translation In Vitro and In Vivo.
Article in Molecular therapy. Nucleic acids, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 71 citations in OpenAlex.
- An Investigation into the Effects of Processing Factors on the Properties and Scaling-Up Potential of Propranolol-Loaded Chitosan Nanogels.Pharmaceutics · 2024Article
- mRNA vaccines: a new era in vaccine development.Oncology research · 2024Review
- New Generation Self-Replicating RNA Vaccines Derived from Pestivirus Genome.Methods in molecular biology (Clifton, N.J.) · 2024Article
- RNA Combined with Nanoformulation to Advance Therapeutic Technologies.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Review
- Self-Amplifying RNA Approach for Protein Replacement Therapy.International journal of molecular sciences · 2022Review
- The Delivery of mRNA Vaccines for Therapeutics.Life (Basel, Switzerland) · 2022Review
- Multimeric RNAs for efficient RNA-based therapeutics and vaccines.Journal of controlled release : official journal of the Controlled Release Society · 2022Review
- Advances in COVID-19 mRNA vaccine development.Signal transduction and targeted therapy · 2022Review
- Modification of Lipid-Based Nanoparticles: An Efficient Delivery System for Nucleic Acid-Based Immunotherapy.Molecules (Basel, Switzerland) · 2022Review
- Review
- Nanotechnologies in Delivery of DNA and mRNA Vaccines to the Nasal and Pulmonary Mucosa.Nanomaterials (Basel, Switzerland) · 2022Review
- Self-amplifying mRNA-Based Vaccine Technology and Its Mode of Action.Current topics in microbiology and immunology · 2022Article
- Lipid nanoparticle-based mRNA vaccines in cancers: Current advances and future prospects.Frontiers in immunology · 2022Review
- Oral mRNA Vaccines Against Infectious Diseases- A Bacterial Perspective [Invited].Frontiers in immunology · 2022Review
- Formulation and Delivery Technologies for mRNA Vaccines.Current topics in microbiology and immunology · 2022Article
- mRNA, a Revolution in Biomedicine.Pharmaceutics · 2021Review
- Revolutionizing polymer-based nanoparticle-linked vaccines for targeting respiratory viruses: A perspective.Life sciences · 2021Review
- Self-amplifying RNA vaccines for infectious diseases.Gene therapy · 2021Review
- mRNA vaccine: a potential therapeutic strategy.Molecular cancer · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Self-amplifying replicon RNA (RepRNA) possesses high potential for increasing antigen load within dendritic cells (DCs). The major aim of the present work was to define how RepRNA delivered by biodegradable, chitosan-based nanoparticulate delivery vehicles (nanogel-alginate (NGA)) interacts with DCs, and whether this could lead to translation of the RepRNA in the DCs. Although studies employed virus replicon particles (VRPs), there are no reports on biodegradable, nanoparticulate vehicle delivery of RepRNA. VRP studies employed cytopathogenic agents, contrary to DC requirements-slow processing and antigen retention. We employed noncytopathogenic RepRNA with NGA, demonstrating for the first time the efficiency of RepRNA association with nanoparticles, NGA delivery to DCs, and RepRNA internalization by DCs. RepRNA accumulated in vesicular structures, with patterns typifying cytosolic release. This promoted RepRNA translation, in vitro and in vivo. Delivery and translation were RepRNA concentration-dependent, occurring in a kinetic manner. Including cationic lipids with chitosan during nanoparticle formation enhanced delivery and translation kinetics, but was not required for translation of immunogenic levels in vivo. This work describes for the first time the characteristics associated with chitosan-nanoparticle delivery of self-amplifying RepRNA to DCs, leading to translation of encoded foreign genes, namely influenza virus hemagglutinin and nucleoprotein.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.